Postmarketing safety of [ 177 Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system

The findings provide new insights into the adverse events of [¹⁷⁷Lu]Lu-PSMA-617 and valuable references for clinical applications of radioligand therapy for mCRPC.